ID

37402

Beschrijving

Vildagliptin Versus Dapagliflozin on Glucagon; ODM derived from: https://clinicaltrials.gov/show/NCT02475070

Link

https://clinicaltrials.gov/show/NCT02475070

Trefwoorden

Versies (1)
  1. 23-07-19 23-07-19 -
Houder van rechten

See clinicaltrials.gov

Geüploaded op

23 juli 2019

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Type 2 Diabetes NCT02475070

Engels

Eligibility Type 2 Diabetes NCT02475070

1 Formulieren  
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. written consent has been given.
Beschrijving

Informed Consent

Datatype

boolean

Alias
UMLS CUI [1]
C0021430
2. patients with type 2 diabetes treated with a stable dose of metformin during the last three months
Beschrijving

Diabetes Mellitus, Non-Insulin-Dependent | Metformin Dose Stable

Datatype

boolean

Alias
UMLS CUI [1]
C0011860
UMLS CUI [2,1]
C0025598
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0205360
3. age 20-70 years.
Beschrijving

Age

Datatype

boolean

Alias
UMLS CUI [1]
C0001779
4. hba1c 6.5-8.5% (48-67 mmol/mol) at visit 1.
Beschrijving

Hemoglobin A1c measurement

Datatype

boolean

Alias
UMLS CUI [1]
C0474680
5. ability to complete the study
Beschrijving

Completion of clinical trial Able

Datatype

boolean

Alias
UMLS CUI [1,1]
C2732579
UMLS CUI [1,2]
C0085732
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. use of other glucose-lowering therapy than metformin within three months prior to visit 1.
Beschrijving

Hypoglycemic Agents | Exception Metformin

Datatype

boolean

Alias
UMLS CUI [1]
C0020616
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0025598
2. a history of any secondary forms of diabetes, e.g., cushing's syndrome and acromegaly.
Beschrijving

Secondary diabetes mellitus | Cushing Syndrome | Acromegaly

Datatype

boolean

Alias
UMLS CUI [1]
C0271640
UMLS CUI [2]
C0010481
UMLS CUI [3]
C0001206
3. type 1 diabetes, positive gad antibodies
Beschrijving

Diabetes Mellitus, Insulin-Dependent | Anti-GAD antibody positive

Datatype

boolean

Alias
UMLS CUI [1]
C0011854
UMLS CUI [2]
C1167896
4. estimated glomerular filtration rate <60 ml/min
Beschrijving

Estimated Glomerular Filtration Rate

Datatype

boolean

Alias
UMLS CUI [1]
C3811844
5. acute infections which may affect blood glucose control within 4 weeks prior to visit 1
Beschrijving

Communicable Diseases Affecting Blood Glucose Control

Datatype

boolean

Alias
UMLS CUI [1,1]
C0009450
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0005802
UMLS CUI [1,4]
C0243148
6. any history of recent (<2 weeks) recurrent or severe hypoglycemic episodes.
Beschrijving

Hypoglycaemic episode Recurrent | Hypoglycaemic episode Severe

Datatype

boolean

Alias
UMLS CUI [1,1]
C0745153
UMLS CUI [1,2]
C2945760
UMLS CUI [2,1]
C0745153
UMLS CUI [2,2]
C0205082
7. any history of acute pancreatitis
Beschrijving

Pancreatitis

Datatype

boolean

Alias
UMLS CUI [1]
C0030305
8. any history of anaphylaxis, angioedema, and exfoliative skin conditions including stevens-johnson syndrome.
Beschrijving

Anaphylaxis | Angioedema | Skin condition Exfoliative | Stevens-Johnson Syndrome

Datatype

boolean

Alias
UMLS CUI [1]
C0002792
UMLS CUI [2]
C0002994
UMLS CUI [3,1]
C1719933
UMLS CUI [3,2]
C0205226
UMLS CUI [4]
C0038325
9. liver disease such as cirrhosis or chronic active hepatitis
Beschrijving

Liver disease | Liver Cirrhosis | Hepatitis, Chronic

Datatype

boolean

Alias
UMLS CUI [1]
C0023895
UMLS CUI [2]
C0023890
UMLS CUI [3]
C0019189
10. history of coronary heart disease or heart failure class iii or iv
Beschrijving

Coronary heart disease | Heart failure New York Heart Association Classification

Datatype

boolean

Alias
UMLS CUI [1]
C0010068
UMLS CUI [2,1]
C0018801
UMLS CUI [2,2]
C1275491
11. donation of one unit (500 ml) or more of blood, significant blood loss equaling to at least one unit of blood within the past 2 weeks or a blood transfusion within the past 8 weeks.
Beschrijving

Blood Donation Unit Quantity | Blood Loss Unit Quantity | Blood Transfusion

Datatype

boolean

Alias
UMLS CUI [1,1]
C0005794
UMLS CUI [1,2]
C0439148
UMLS CUI [1,3]
C1265611
UMLS CUI [2,1]
C3163616
UMLS CUI [2,2]
C0439148
UMLS CUI [2,3]
C1265611
UMLS CUI [3]
C0005841
12. treatment with growth hormone of chronic oral or parenteral corticosteroid treatment (> 7 consecutive days of treatment) within 8 weeks prior to visit 1.
Beschrijving

Growth hormone treatment | Steroid therapy oral chronic | Steroid therapy parenteral chronic

Datatype

boolean

Alias
UMLS CUI [1]
C0744483
UMLS CUI [2,1]
C0149783
UMLS CUI [2,2]
C1527415
UMLS CUI [2,3]
C0205191
UMLS CUI [3,1]
C0149783
UMLS CUI [3,2]
C1518896
UMLS CUI [3,3]
C0205191
13. use of other investigational drugs at visit 1 or within 30 days of visit 1, unsuitable for the study
Beschrijving

Investigational New Drugs Inappropriate Clinical Trial

Datatype

boolean

Alias
UMLS CUI [1,1]
C0013230
UMLS CUI [1,2]
C1548788
UMLS CUI [1,3]
C0008976
14. hypersensitivity to vildagliptin or dapagliflozin or any compound in the tablet core
Beschrijving

Hypersensitivity Vildagliptin | Hypersensitivity Dapagliflozin | Hypersensitivity Compound Investigational New Drugs

Datatype

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C1570906
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C2353951
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C1706082
UMLS CUI [3,3]
C0013230
Terug naar het begin van de pagina

Similar models

Eligibility Type 2 Diabetes NCT02475070

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
1. written consent has been given.
boolean
C0021430 (UMLS CUI [1])
Diabetes Mellitus, Non-Insulin-Dependent | Metformin Dose Stable
Item
2. patients with type 2 diabetes treated with a stable dose of metformin during the last three months
boolean
C0011860 (UMLS CUI [1])
C0025598 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
Age
Item
3. age 20-70 years.
boolean
C0001779 (UMLS CUI [1])
Hemoglobin A1c measurement
Item
4. hba1c 6.5-8.5% (48-67 mmol/mol) at visit 1.
boolean
C0474680 (UMLS CUI [1])
Completion of clinical trial Able
Item
5. ability to complete the study
boolean
C2732579 (UMLS CUI [1,1])
C0085732 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Hypoglycemic Agents | Exception Metformin
Item
1. use of other glucose-lowering therapy than metformin within three months prior to visit 1.
boolean
C0020616 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0025598 (UMLS CUI [2,2])
Secondary diabetes mellitus | Cushing Syndrome | Acromegaly
Item
2. a history of any secondary forms of diabetes, e.g., cushing's syndrome and acromegaly.
boolean
C0271640 (UMLS CUI [1])
C0010481 (UMLS CUI [2])
C0001206 (UMLS CUI [3])
Diabetes Mellitus, Insulin-Dependent | Anti-GAD antibody positive
Item
3. type 1 diabetes, positive gad antibodies
boolean
C0011854 (UMLS CUI [1])
C1167896 (UMLS CUI [2])
Estimated Glomerular Filtration Rate
Item
4. estimated glomerular filtration rate <60 ml/min
boolean
C3811844 (UMLS CUI [1])
Communicable Diseases Affecting Blood Glucose Control
Item
5. acute infections which may affect blood glucose control within 4 weeks prior to visit 1
boolean
C0009450 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0005802 (UMLS CUI [1,3])
C0243148 (UMLS CUI [1,4])
Hypoglycaemic episode Recurrent | Hypoglycaemic episode Severe
Item
6. any history of recent (<2 weeks) recurrent or severe hypoglycemic episodes.
boolean
C0745153 (UMLS CUI [1,1])
C2945760 (UMLS CUI [1,2])
C0745153 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
Pancreatitis
Item
7. any history of acute pancreatitis
boolean
C0030305 (UMLS CUI [1])
Anaphylaxis | Angioedema | Skin condition Exfoliative | Stevens-Johnson Syndrome
Item
8. any history of anaphylaxis, angioedema, and exfoliative skin conditions including stevens-johnson syndrome.
boolean
C0002792 (UMLS CUI [1])
C0002994 (UMLS CUI [2])
C1719933 (UMLS CUI [3,1])
C0205226 (UMLS CUI [3,2])
C0038325 (UMLS CUI [4])
Liver disease | Liver Cirrhosis | Hepatitis, Chronic
Item
9. liver disease such as cirrhosis or chronic active hepatitis
boolean
C0023895 (UMLS CUI [1])
C0023890 (UMLS CUI [2])
C0019189 (UMLS CUI [3])
Coronary heart disease | Heart failure New York Heart Association Classification
Item
10. history of coronary heart disease or heart failure class iii or iv
boolean
C0010068 (UMLS CUI [1])
C0018801 (UMLS CUI [2,1])
C1275491 (UMLS CUI [2,2])
Blood Donation Unit Quantity | Blood Loss Unit Quantity | Blood Transfusion
Item
11. donation of one unit (500 ml) or more of blood, significant blood loss equaling to at least one unit of blood within the past 2 weeks or a blood transfusion within the past 8 weeks.
boolean
C0005794 (UMLS CUI [1,1])
C0439148 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C3163616 (UMLS CUI [2,1])
C0439148 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C0005841 (UMLS CUI [3])
Growth hormone treatment | Steroid therapy oral chronic | Steroid therapy parenteral chronic
Item
12. treatment with growth hormone of chronic oral or parenteral corticosteroid treatment (> 7 consecutive days of treatment) within 8 weeks prior to visit 1.
boolean
C0744483 (UMLS CUI [1])
C0149783 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C0205191 (UMLS CUI [2,3])
C0149783 (UMLS CUI [3,1])
C1518896 (UMLS CUI [3,2])
C0205191 (UMLS CUI [3,3])
Investigational New Drugs Inappropriate Clinical Trial
Item
13. use of other investigational drugs at visit 1 or within 30 days of visit 1, unsuitable for the study
boolean
C0013230 (UMLS CUI [1,1])
C1548788 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,3])
Hypersensitivity Vildagliptin | Hypersensitivity Dapagliflozin | Hypersensitivity Compound Investigational New Drugs
Item
14. hypersensitivity to vildagliptin or dapagliflozin or any compound in the tablet core
boolean
C0020517 (UMLS CUI [1,1])
C1570906 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C2353951 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C1706082 (UMLS CUI [3,2])
C0013230 (UMLS CUI [3,3])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial